Aclaris Therapeutics, Inc. entered into a Sales Agreement with SVB Securities LLC and Cantor Fitzgerald & Co. to offer and sell shares of its common stock up to $200 million, and terminated a prior Sales Agreement for the sale of $150 million of Common Stock.